Press release
Duchenne Muscular Dystrophy (DMD) Therapeutics Market Focusing on Top Key Players - Eli Lilly and Company, Pfizer, Inc., and BioMarin Pharmaceutical, Inc
Duchenne Muscular Dystrophy (DMD) is the serious type of muscle diseases that affects the male population at the age of four and make them lose their ability to walk by 12. Due to its rare effects, it is termed as orphan diseases and can be found for approximately 1 in 3,500 male population. Compared to the previous decade, several new treatment methods have been developed recently to detect and treat the diseases, which is collectively known as Duchenne muscular dystrophy (DMD) therapeutics.
Request free sample @ https://www.researchcosmos.com/request/global-duchenne-muscular-dystrophy-therapeutics-market-outlo/4958600
Factors Driving the Growth of Global Duchenne Muscular Dystrophy Therapeutics Market:
The average life expectancy of the children affected by this muscular dystrophy is 26 years, however, it can be extended to 30 years or 40 years with regular medical care. The general symptoms of this disease include weakness in muscles of the hips, pelvic area, thighs, shoulders, arms, legs, and trunk. Although there is no cure for this diseases, new therapeutics have been developed to control its progression in the body. Molecular-based therapies like mutation suppression or exon skipping are the most common treatments for the Duchenne Muscular Dystrophy (DMD).
There are some significant factors driving the global Duchenne Muscular Dystrophy (DMD) therapeutics market such as the increasing development of new drugs, rise in the research and development, growing demand for the therapeutics among the patients, mounting cases of other chronic diseases cardiovascular, neurovascular, and arthritis, increasing availability health insurance, growth in the health care spending of the people, and so on. However, the delayed process for the prognosis is the major restraining aspect of the market expansion.
Browse details of 80 pages research report developed on Global Duchenne Muscular Dystrophy Market @ https://www.researchcosmos.com/reports/global-duchenne-muscular-dystrophy-therapeutics-market-outlo/4958600
Geographic Segmentation:
Based on the geography, North America accounts for the largest share of the global Duchenne Muscular Dystrophy therapeutics market due to the launch of innovative products, healthcare expenditure, investments in the research and development, and government supportive initiatives. Europe is next in line to North America, and the Asia Pacific region is expected to register higher growth rate in the future.
Some of the Leading Companies in the Global Duchenne Muscular Dystrophy Therapeutics Market:
Some of the leading contributors to the global Duchenne Muscular Dystrophy therapeutics market are Eli Lilly and Company, Pfizer, Inc., Santhera Pharmaceuticals Holding, Nobelpharma Co., Ltd., Sarepta Therapeutics, Inc., Tivorsan Pharmaceuticals, Acceleron Pharma, Inc., Asklepios Kliniken GmbH, FibroGen, Inc., and BioMarin Pharmaceutical, Inc.
About Us:
Research Cosmos is a provider of standard and customized market research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending market reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.
Contact:
Kevin Stewart
Global Sales Manager
Research Cosmos
www.researchcosmos.com
Blog: https://acutemarketinsights.com
Blog: https://marketreportsweb.com/
kevin@researchcosmos.com
+1 888 709 8757
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy (DMD) Therapeutics Market Focusing on Top Key Players - Eli Lilly and Company, Pfizer, Inc., and BioMarin Pharmaceutical, Inc here
News-ID: 1221234 • Views: …
More Releases from Research Cosmos
Mobile Phone Insurance Market Size to Reach USD 32.24 Bn By 2025
The size of the Global mobile phone insurance market is estimated to reach USD 32.24 billion by 2025, growing at a CAGR of 12.5%, as per the recently published report by Research Cosmos. It is worth to claim insurance for mobile phones as we are spending a lot of money on purchasing. The policies include accidental damage, water damage, and screen cracking.
Browse details of the report @ https://www.researchcosmos.com/reports/mobile-phone-insurance-market/199557834
Growing utilization…
Social Employee Recognition Systems Market Predicted to grow at a CAGR of xx By …
Social Employee Recognition Systems Market Analysis Size, Growth rate and Overview:
Social Employee Recognition Systems Market was valued at USD xx million in 2018 and is expected to reach almost USD xx million by the end of 2025, growing at a CAGR of around xx% over the predicted period.
Throughout the world, social employee recognition systems have expanded dramatically to address the need to move away from traditional methods and programs of…
More Releases for Duchenne
Emerging Trends Influencing The Growth Of The Duchenne Muscular Dystrophy (DMD) …
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Expected to Be by 2034?
In recent times, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant…
Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dyst …
What industry-specific factors are fueling the growth of the duchenne muscular dystrophy market?
The rise in chronic diseases is projected to stimulate the expansion of the Duchenne muscular dystrophy market in the coming years. Chronic diseases are health complications that endure for a minimum of a year. Duchenne muscular dystrophy is instrumental in the increase of chronic diseases as it addresses the unique therapeutic requirements of those suffering from this genetic…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market…
